icometrix has received approval for icobrain as a medical device in Canada and Japan. This comes after the recent FDA and CE approval for the reports providing healthcare professionals with quantitative MRI measures to aid the diagnosis of dementia.
“The recent approvals do not only allow us to help a larger number of clinicians and patients. It also underlines the efforts we take in developing and providing reliable, validated biomarkers which can be used in clinical practice.” says Wim Van Hecke, CEO at icometrix.
Dementia is a known challenge in both countries. While Canada expects almost 1 million dementia cases in 2031, Japan is expected to have 7 million cases by 2025.
“The new icobrain measures can aid the diagnosis of the fast-growing dementia population in both countries. Timely diagnosis and early intervention are crucial. In Japan, our collaboration with Micron will allow doctors and patients easy access to our analysis.” Van Hecke continues.
Alongside icobrain ms, which is already the established standard for clinicians treating multiple sclerosis, icobrain dm can now also provide clinically meaningful data to the benefit of dementia patients globally.
“icometrix will continue to provide our best-in-class measures for MS. The great feedback we get from this makes us very proud and motivated to extend the analysis to dementia.” concludes Van Hecke.Back to news